Much progress has been made in recent years into the impact of genetics on cancer and its treatment. Advances have also been made in finding ways to incorporate the patients' subjective experience into clinical research. Indeed, validated quality-of-life instruments are now available and empirical evidence about disease and treatment outcomes has been collected for most disease sites and treatment modalities. Perhaps the most provocative finding is that quality of life can be superior to clinical assessments for predicting cancer patients’ survival.

Recent data provided preliminary evidence that the genetic disposition of cancer patients may impact their quality of life. This one-day course will explore the genetic disposition of quality of life in cancer patients by reviewing the evidence and setting a research agenda for identifying potential genes and genetic variants for quality of life.

Program Directors
Jeff A. Sloan, Ph.D. - Mayo Clinic
Mirjam Sprangers, Ph.D. - University of Amsterdam, the Netherlands

For more information visit http://www.mayo.edu/cme or email cme@mayo.edu